Colorectal Cancer

Oncology
131
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
17
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
24
19
43
5
20
20
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2263%
Small Molecule
926%
Cell Therapy
411%
+ 118 programs with unclassified modality

On Market (17)

Approved therapies currently available

Roche
AVASTINApproved
bevacizumab
Roche
Vascular Endothelial Growth Factor Inhibitor [EPC]intravenous2004
Pfizer
CAMPTOSARApproved
irinotecan hydrochloride
Pfizer
injection1996
Eli Lilly and Company
CYRAMZAApproved
ramucirumab
Eli Lilly and Company
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]injection2014
U
DEXAMETHASONEApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]oral2023
U
DEXONE 0.5Approved
dexamethasone
Unknown Company
oral
U
DEXONE 0.75Approved
dexamethasone
Unknown Company
oral
U
DEXONE 1.5Approved
dexamethasone
Unknown Company
oral1975
U
DEXONE 4Approved
dexamethasone
Unknown Company
oral
U
DEXYCU KITApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]intraocular2018
U
EFUDEXApproved
fluorouracil
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]topical1970
U
ERBITUXApproved
cetuximab
Unknown Company
Epidermal Growth Factor Receptor Antagonist [EPC]intravenous2004
U
FLUOROPLEXApproved
fluorouracil
Unknown Company
topical1970
U
FLUOROURACILApproved
fluorouracil
Unknown Company
injection
Takeda
FRUZAQLAApproved
fruquintinib
Takeda
oral2023
Novartis
IRINOTECAN HYDROCHLORIDEApproved
irinotecan hydrochloride
Novartis
injection2008
U
MAXIDEXApproved
dexamethasone
Unknown Company
Corticosteroid [EPC]ophthalmic1962
U
TOLAKApproved
fluorouracil
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]topical2015

Competitive Landscape

65 companies ranked by most advanced pipeline stage

Roche
7 programs
1
1
4
1
AVASTIN(Bevacizumab)Phase 3Monoclonal Antibody5 trials
ChemotherapyPhase 33 trials
bevacizumab [Avastin]Phase 31 trial
oxaliplatin+capecitabinePhase 3
OxaliplatinPhase 21 trial
+2 more programs
Active Trials
NCT01801085Terminated21Est. Dec 2014
NCT03866239Terminated47Est. Mar 2024
NCT00159432Completed63Est. Mar 2013
+9 more trials
Pfizer
PfizerNEW YORK, NY
7 programs
1
3
1
2
1
FOLFIRI regimenPhase 31 trial
fluorouracilPhase 31 trial
FOLFIRIPhase 2/3
FUFAPhase 21 trial
LGX818Phase 21 trial
+2 more programs
Active Trials
NCT00522665Completed41Est. Feb 2015
NCT01212718Completed168Est. Sep 2010
NCT01719380Completed156Est. Feb 2019
+7 more trials
M&
6 programs
2
2
1
CetuximabPhase 4Monoclonal Antibody1 trial
Encorafenib Oral Capsule + CetuximabPhase 2Monoclonal Antibody1 trial
PembrolizumabPhase 2Monoclonal Antibody1 trial
M9140Phase 12 trials
MK0457, VX-680Phase 11 trial
+1 more programs
Active Trials
NCT02045680Unknown30Est. Dec 2014
NCT06710132RecruitingEst. Dec 2027
NCT05464030Recruiting200Est. Feb 2027
+4 more trials
Takeda
TakedaTOKYO, Japan
5 programs
1
1
FruquintinibPhase 4Small Molecule1 trial
Panitumumab + TAS-102Phase 1/21 trial
TAK-113N/A1 trial
mFOLFOX6 + panitumumab combination therapyN/A1 trial
oxaliplatinN/A3 trials
Active Trials
NCT06195514No Longer Available
NCT05030493Active Not Recruiting787Est. Jul 2027
NCT02394834Active Not Recruiting757Est. Mar 2026
+4 more trials
Novartis
3 programs
1
1
1
1
irinotecan hydrochloridePhase 31 trial
EverolimusPhase 21 trial
GevokizumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03798626Completed167Est. Feb 2025
NCT00419159Completed199Est. Mar 2009
NCT00006269Terminated89
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
3 programs
1
2
1
RamucirumabPhase 3Monoclonal Antibody1 trial
cetuximabPhase 3Monoclonal Antibody1 trial
GemcitabinePhase 21 trial
Active Trials
NCT00192075Completed84Est. Nov 2007
NCT03520946Completed430Est. Jul 2024
NCT00061815Completed102Est. Nov 2005
Recordati
RecordatiFrance - Saint-Victor
1 program
1
PlenvuPhase 41 trial
Active Trials
NCT04297423Completed1,002Est. Jun 2022
Alliance Pharmaceuticals
10 programs
2
2
dexamethasonePhase 31 trial
irinotecanPhase 35 trials
SN-38 liposomePhase 21 trial
fluorouracilPhase 21 trial
DNA stability analysisN/A1 trial
+5 more programs
Active Trials
NCT00014079Completed675Est. May 2005
NCT00003833Completed598Est. Aug 2006
NCT00003648Completed1,500Est. May 2006
+17 more trials
Sanofi
SanofiPARIS, France
4 programs
1
1
2
irinotecan hydrochloridePhase 31 trial
oxaliplatin+capecitabinePhase 31 trial
FOLFIRIPhase 2/3
5-FUPhase 25 trials
Active Trials
NCT03530267Completed124Est. Feb 2024
NCT01889680Withdrawn0Est. May 2018
NCT01882868Completed62Est. Aug 2015
+4 more trials
Cosmo Pharmaceuticals
Cosmo PharmaceuticalsIreland - Dublin
3 programs
1
1
Methylene Blue MMX®Phase 31 trial
standard white light colonoscopy-equivalent to placeboPhase 21 trial
CB-17-08 CADeN/A1 trial
Active Trials
NCT03954548CompletedEst. May 2021
NCT02295774CompletedEst. Dec 2014
NCT01694966CompletedEst. Oct 2016
H
3 programs
1
1
1
fruquintinibPhase 3Small Molecule1 trial
fruquintinibPhase 2Small Molecule1 trial
fruquintinibPhase 1/2Small Molecule1 trial
Active Trials
NCT01975077Completed62Est. Oct 2014
NCT02196688Completed71Est. Nov 2015
NCT02314819Completed416Est. Jan 2017
Taiho Oncology
2 programs
1
1
TAS-102Phase 31 trial
TAS-102Phase 1/21 trial
Active Trials
NCT03223779Active Not RecruitingEst. Jan 2026
NCT01607957CompletedEst. May 2016
Egetis Therapeutics
2 programs
2
CalmangafodipirPhase 31 trial
CalmangafodipirPhase 31 trial
Active Trials
NCT04034355TerminatedEst. Aug 2020
NCT03654729TerminatedEst. Aug 2020
Chipscreen Biosciences
1 program
1
TucidinostatPhase 3Small Molecule1 trial
Active Trials
NCT06497985RecruitingEst. Sep 2028
One Biosciences
1 program
1
fruquintinibPhase 3Small Molecule
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
1
2
1
CediranibPhase 2/3Small Molecule5 trials
AZD2171Phase 21 trial
AmifostinePhase 21 trial
ZD6474Phase 11 trial
Active Trials
NCT00436072Completed46Est. Aug 2012
NCT00278889Completed215Est. Oct 2009
NCT00601198Terminated4Est. Jan 2010
+5 more trials
DS
3 programs
2
1
CPT-11 and TS-1Phase 2/31 trial
CS7017Phase 21 trial
DJ-927Phase 22 trials
Active Trials
NCT00967616Completed100Est. Apr 2013
NCT00080834CompletedEst. Aug 2006
NCT00077077CompletedEst. Jan 2006
+1 more trials
CP
Chugai PharmaJapan - Tokyo
2 programs
1
1
FOLFIRIPhase 2/31 trial
BevacizumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00345761Completed64Est. Jul 2010
NCT00208260Completed124Est. Aug 2007
Amgen
5 programs
1
4
ABX-EGFPhase 23 trials
IrinotecanPhase 21 trial
panitumumabPhase 2Monoclonal Antibody1 trial
panitumumabPhase 2Monoclonal Antibody1 trial
Dacogen™Phase 11 trial
Active Trials
NCT00879385Completed21Est. Jan 2013
NCT00113776Completed
NCT00101920Completed50Est. Dec 2004
+4 more trials
Pierre Fabre
Pierre FabreFrance - Aignan
4 programs
4
BinimetinibPhase 2Small Molecule
CetuximabPhase 2Monoclonal Antibody1 trial
EBCPhase 2
Encorafenib Oral Capsule + CetuximabPhase 2Monoclonal Antibody
Active Trials
NCT06578559Active Not Recruiting16Est. Apr 2027
E
3 programs
1
1
1
E7070Phase 21 trial
FOLFIRIPhase 1/21 trial
Dacogen™Phase 1
Active Trials
NCT01133990Terminated5Est. Feb 2011
NCT00165867Completed40
Genentech
3 programs
1
2
CapecitabinePhase 21 trial
panitumumabPhase 2Monoclonal Antibody
FOLFIRI regimenPhase 11 trial
Active Trials
NCT00671372Completed42Est. Mar 2012
NCT00203411Completed45Est. Mar 2011
Galectin Therapeutics
3 programs
1
2
GM-CT-01Phase 21 trial
GM-CT-01 plus 5-FluorouracilPhase 21 trial
GM-CT-01Phase 11 trial
Active Trials
NCT00054977CompletedEst. Sep 2006
NCT00388700WithdrawnEst. Jun 2009
NCT00110721TerminatedEst. Feb 2008
AbbVie
AbbVieNORTH CHICAGO, IL
3 programs
1
1
1
Telisotuzumab AdizutecanPhase 25 trials
Telisotuzumab AdizutecanPhase 1/21 trial
SC-006Phase 11 trial
Active Trials
NCT03035279Terminated29Est. Mar 2019
NCT06464692Recruiting30Est. Sep 2028
NCT07155187Recruiting430Est. Sep 2030
+4 more trials
CT
3 programs
2
1
Anlotinib HydrochloridePhase 21 trial
TQB2618 injectionPhase 11 trial
Trifluridine and Tipiracil TabletsPhase 11 trial
Active Trials
NCT06010901UnknownEst. Jul 2025
NCT03974594CompletedEst. Jul 2019
NCT04080843CompletedEst. Jul 2022
GS
Gilead SciencesFOSTER CITY, CA
3 programs
2
1
SimtuzumabPhase 2Monoclonal Antibody1 trial
hMN14Phase 1/23 trials
hMN14Phase 1/2
Active Trials
NCT00041652Completed30Est. Jun 2003
NCT00041639Completed75Est. Dec 2003
NCT00040599Completed72Est. Jan 2004
+1 more trials
KARL STORZ Endoscopy
2 programs
1
1
CysviewPhase 21 trial
hexaminolevulinatePhase 1/21 trial
Active Trials
NCT00285701CompletedEst. Mar 2008
NCT03272659WithdrawnEst. Apr 2019
Bristol Myers Squibb
2 programs
2
Capecitabine and CetuximabPhase 2Monoclonal Antibody1 trial
CetuximabPhase 2Monoclonal Antibody5 trials
Active Trials
NCT00251186Terminated18Est. Apr 2006
NCT00251498Completed82Est. Oct 2007
NCT07223047Recruiting252Est. Oct 2028
+3 more trials
Regeneron
RegeneronTARRYTOWN, NY
2 programs
2
CemiplimabPhase 2Monoclonal Antibody1 trial
OxaliplatinPhase 21 trial
Active Trials
NCT06205836Recruiting33Est. May 2028
NCT07281768Not Yet Recruiting66Est. Mar 2030
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
NKTR-102Phase 21 trial
Active Trials
NCT00856375CompletedEst. Dec 2014

+35 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Merck & Co.Cetuximab
TakedaFruquintinib
RecordatiPlenvu
RocheBevacizumab
RocheBevacizumab
RocheBevacizumab
RocheBevacizumab
RocheBevacizumab
RocheBevacizumab
Chipscreen BiosciencesTucidinostat
RocheBevacizumab
RocheBevacizumab
RocheBevacizumab
Eli Lilly and CompanyRamucirumab
RocheBevacizumab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 25,170 patients across 50 trials

NCT07094893Merck & Co.Cetuximab

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Start: Apr 2026Est. completion: Mar 2030280 patients
Phase 4Not Yet Recruiting
NCT06562543TakedaFruquintinib

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Start: Jan 2025Est. completion: Oct 202778 patients
Phase 4Recruiting
NCT04297423RecordatiPlenvu

Two Low Volume Regimens for Colorectal Cancer Screening Colonoscopy

Start: Mar 2020Est. completion: Jun 20221,002 patients
Phase 4Completed
NCT01932125RocheBevacizumab

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Start: Dec 2018Est. completion: Jun 2025100 patients
Phase 4Completed
NCT00577031RocheBevacizumab

OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.

Start: Feb 2008Est. completion: Aug 2011205 patients
Phase 4Completed
NCT00451906RocheBevacizumab

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Start: Aug 2006Est. completion: Jun 20092,252 patients
Phase 4Completed
NCT00121836RocheBevacizumab

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

Start: Jun 2005Est. completion: Dec 2008109 patients
Phase 4Completed
NCT02582970RocheBevacizumab

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

Start: May 2005Est. completion: Apr 200840 patients
Phase 4Completed
NCT06680258RocheBevacizumab

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Start: Dec 2025Est. completion: Jul 2030740 patients
Phase 3Not Yet Recruiting
NCT06497985Chipscreen BiosciencesTucidinostat

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Start: Nov 2024Est. completion: Sep 2028
Phase 3Recruiting
NCT06733038RocheBevacizumab

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Start: Nov 2024Est. completion: Apr 2029238 patients
Phase 3Recruiting
NCT04770896RocheBevacizumab

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Start: Apr 2021Est. completion: Jun 2026557 patients
Phase 3Active Not Recruiting
NCT04712643RocheBevacizumab

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Start: Mar 2021Est. completion: Feb 2029342 patients
Phase 3Active Not Recruiting
NCT03520946Eli Lilly and CompanyRamucirumab

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Start: Jan 2019Est. completion: Jul 2024430 patients
Phase 3Completed
NCT03693573RocheBevacizumab

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Start: Jan 2019Est. completion: Jan 20240
Phase 3Withdrawn
NCT04034355Egetis TherapeuticsCalmangafodipir

Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer

Start: Jan 2019Est. completion: Aug 2020
Phase 3Terminated
NCT03654729Egetis TherapeuticsCalmangafodipir

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

Start: Nov 2018Est. completion: Aug 2020
Phase 3Terminated
NCT03556839RocheBevacizumab

Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Start: Sep 2018Est. completion: Aug 2025410 patients
Phase 3Active Not Recruiting
NCT03434379RocheBevacizumab

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Start: Mar 2018Est. completion: Nov 2022558 patients
Phase 3Completed
NCT02446600AstraZenecaCediranib

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start: Mar 2016Est. completion: Nov 2026579 patients
Phase 3Active Not Recruiting
NCT02394795Takedaoxaliplatin

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Start: May 2015Est. completion: Jan 2022823 patients
Phase 3Completed
NCT02420821RocheBevacizumab

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Start: May 2015Est. completion: Dec 2021915 patients
Phase 3Completed
NCT02366143RocheBevacizumab

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Start: Mar 2015Est. completion: Dec 20201,202 patients
Phase 3Completed
NCT02314819Hutchmedfruquintinib

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

Start: Dec 2014Est. completion: Jan 2017416 patients
Phase 3Completed
NCT01694966Cosmo PharmaceuticalsMethylene Blue MMX®

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Start: Sep 2013Est. completion: Oct 2016
Phase 3Completed
NCT01931150Bristol Myers SquibbCetuximab

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Start: Aug 2013Est. completion: Sep 201511 patients
Phase 3Completed
NCT01607957Taiho OncologyTAS-102

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Start: Jun 2012Est. completion: May 2016
Phase 3Completed
NCT01290939RocheBevacizumab

Bevacizumab and Lomustine for Recurrent GBM

Start: Oct 2011Est. completion: Apr 2020592 patients
Phase 3Completed
NCT01239732RocheBevacizumab

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Start: Dec 2010Est. completion: Mar 20151,021 patients
Phase 3Completed
NCT01229813RocheBevacizumab

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

Start: Oct 2010Est. completion: Dec 2013233 patients
Phase 3Completed
NCT00777153AstraZenecaCediranib

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

Start: Oct 2008Est. completion: Sep 2016423 patients
Phase 3Completed
NCT00625898RocheBevacizumab

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Start: Apr 2008Est. completion: Jul 20143,509 patients
Phase 3Terminated
NCT00623805RocheBevacizumab

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer

Start: Mar 2008Est. completion: May 2012123 patients
Phase 3Completed
NCT00528567RocheBevacizumab

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

Start: Dec 2007Est. completion: Jun 20142,591 patients
Phase 3Completed
NCT00545077RocheBevacizumab

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Start: Nov 2007Est. completion: Jul 2014380 patients
Phase 3Completed
NCT00642577Rochebevacizumab [Avastin]

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.

Start: Jul 2007Est. completion: Dec 2010214 patients
Phase 3Completed
NCT00484939RocheBevacizumab

A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

Start: Jul 2007Est. completion: Mar 2013280 patients
Phase 3Completed
NCT00532194AstraZenecaCediranib

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Start: Jul 2007Est. completion: Dec 2016486 patients
Phase 3Unknown
NCT00442637RocheBevacizumab

Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma

Start: Jan 2007Est. completion: Dec 2013635 patients
Phase 3Unknown
NCT00394992Sanofioxaliplatin+capecitabine

Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

Start: Dec 2006Est. completion: Aug 201379 patients
Phase 3Terminated
NCT00399035AstraZenecaCediranib

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

Start: Nov 2006Est. completion: Aug 20161,254 patients
Phase 3Completed
NCT00391092RocheBevacizumab

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Start: Sep 2006Est. completion: Aug 2014424 patients
Phase 3Completed
NCT00349336RocheBevacizumab

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Start: Aug 2006Est. completion: Nov 200864 patients
Phase 3Completed
NCT01169558RocheBevacizumab

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.

Start: May 2006Est. completion: Jul 2009168 patients
Phase 3Completed
NCT00700102RocheChemotherapy

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Start: Feb 2006Est. completion: May 2013820 patients
Phase 3Completed
NCT00252564Bristol Myers SquibbCetuximab

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Start: Sep 2005Est. completion: Jun 2009247 patients
Phase 3Completed
NCT00077233Alliance Pharmaceuticalsirinotecan

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Start: Dec 2003Est. completion: Jun 2010238 patients
Phase 3Terminated
NCT00061815Eli Lilly and Companycetuximab

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Start: Mar 2003Est. completion: Nov 2005102 patients
Phase 3Completed
NCT00026273PfizerFOLFIRI regimen

Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer

Start: Jan 2001
Phase 3Completed
NCT00012389Sanofiirinotecan hydrochloride

Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

Start: Dec 2000Est. completion: Oct 2008
Phase 3Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

20 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 25,170 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Advanced Solid Tumor(165)Solid Tumors(158)